The 20 Best Gastroesophageal Junction Cancer Doctors Near Me in Maryland, US

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer. Dr. Le is board certified in American Board Of Internal Medicine.

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Feliciano is board certified in American Board Of Internal Medicine.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy. Dr. Azad is board certified in American Board Of Internal Medicine.

Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 23 other conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy. Dr. Browner is board certified in American Board Of Internal Medicine.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Anal Cancer, Gastrointestinal Fistula, Colostomy, and Ileostomy. Dr. Migaly is board certified in American Board Of Colon And Rectal Surgery and American Board Of Surgery.

Ana De Jesus is an Oncologist practicing medicine in Baltimore, Maryland. Dr. De Jesus is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. De Jesus is board certified in American Board Of Internal Medicine.

Yudhishtra Markan is a Hematologist Oncology specialist and an Oncologist practicing medicine in Glen Burnie, Maryland. Dr. Markan is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Markan is board certified in American Board Of Internal Medicine.

Thomas Lank is a Radiologist practicing medicine in Annapolis, Maryland. Dr. Lank is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Thyroid Nodule, Neonatal Ovarian Cyst, Baker Cyst, and Visceromegaly.

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is board certified in American Board Of Internal Medicine.

Blanche Mavromatis, MD, specializes in hematology oncology and is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mavromatis completed her fellowship at Georgetown University Hospital, residency at Georgetown University Medical Center and medical degree from Thomas Jefferson University Medical College. Dr. Mavromatis is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 67 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Mavromatis is board certified in American Board Of Internal Medicine. Dr. Mavromatis is currently accepting new patients.

Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Donehower is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery. Dr. Donehower is board certified in American Board Of Internal Medicine.

William Houck is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 73 other conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Houck is board certified in American Board Of Internal Medicine.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery. Dr. Kleinberg is board certified in American Board Of Radiology.

Fellowship trained in both colon and rectal surgery, Dr. Somerville has been in practice since 2005. He specializes in colorectal cancer, diverticular disease and IBD, and is an advanced laparoscopic/minimally invasive surgeon with extensive experience treating a broad range of anorectal diseases, as well. www.somsurgery.com. Dr. Somerville is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, Bladder Reconstruction, and Small Bowel Resection. Dr. Somerville is board certified in American Board Of Colon And Rectal Surgery and American Board Of Surgery.

"A colorectal surgeon, Dr. Bafford specializes in the treatment of colorectal cancer, inflammatory bowel disease, and benign diseases of the colon, rectum and anus. ""These diseases are very treatable. The surgeries I perform are effective at curing cancer or treating colitis, which allows my patients back to the quality of life they want to have. It's very rewarding to see that type of recovery with so many of my patients,"" she says. Dr. Bafford's special interests include laparoscopic and robotic minimally invasive surgery, approaches that are associated with less pain and a faster recovery. Treatments she offers include surgical treatment of inflammatory bowel disease, sphincter-sparing surgery and organ preservation for rectal cancer, surgery for anorectal disorders, minimally invasive surgery for diverticulitis, treatment of rectal prolapse, and screening and therapeutic colonoscopy. Dr. Bafford has authored or co-authored numerous publications in leading peer-reviewed scientific journals and textbooks. Her research interests are in the pathophysiology of colorectal cancer, disparities in colorectal surgery and the surgical management of inflammatory bowel disease. Her passion and dedication have earned her a consistent spot on Baltimore magazine's ""Top Doctor"" lists for colon and rectal surgery. Videos Andrea Chao Bafford M.D.Colorectal Surgeon Research Summary Dr. Bafford's research has largely focused on IBD. Utilizing institutional databases and the NSQIP IBD, she has investigated perioperative outcomes in IBD patients as they relate to sex, immunosuppressive medical therapy, trauma, preoperative drainage of abscesses, and fecal diversion. She has also published on the microbiota of perianal Crohn’s disease with the help of an intramural grant. In addition, through interdepartmental collaboration, Dr. Bafford has contributed towards intestinal organoid preparation and 3D colon cancer organoid development used to study immune responses to intestinal infections, intestinal immunity, and colon cancer pathogenesis.". Dr. Bafford is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Crohn's Disease, Ulcerative Colitis, Familial Colorectal Cancer, Hernia Surgery, and Ileostomy. Dr. Bafford is board certified in American Board Of Colon And Rectal Surgery and American Board Of Surgery.

Dr. Stefan Loy Zimmerman is a Professor in the Johns Hopkins University School of Medicine in the Departments of Radiology and Medicine (Cardiology). He specializes in cardiothoracic imaging and is the Division Director of Diagnostic Imaging and Director of Cardiac Imaging. He is the program director for the Cardiothoracic Imaging Fellowship in Radiology. Dr. Zimmerman earned his medical degree from the University of Pennsylvania School of Medicine. He completed both a radiology residency and a cardiovascular imaging fellowship at the Hospital of the University of Pennsylvania. His research focuses on the use of CT and MR imaging in the diagnosis and management of cardiovascular diseases. He has particular interest in the use of cardiac imaging for management of arrhythmias, diagnosis and prognosis of arrhythmogenic right and left ventricular cardiomyopathy, and pulmonary hypertension. Dr. Zimmerman is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Supraventricular Tachycardia (PSVT), Rhabdomyosarcoma, Synovial Sarcoma, Cardiac Ablation, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Zimmerman is board certified in American Board Of Radiology.

Richard Battafarano, M.D., Ph.D., joins the Johns Hopkins Department of Surgery as director of the Division of General Thoracic Surgery and the first regional director of general thoracic surgery. He comes to Johns Hopkins from University of Maryland Medical System, where he was chief of the Division of Thoracic Surgery. Dr. Battafarano specializes in the treatment of benign and malignant diseases and lesions of the chest, including minimally invasive operations such as video-assisted thoracscopic surgery (VATS) for lung and esophageal cancers. He also has a special interest in treating Barretts esophagus, emphysema, mesothelioma and paraesophageal hernias. The focus of Dr. Battafaranos basic and translational research includes outcomes in the surgical management of early stage lung cancer patients with neuroendocrine histology, optimal management of lung cancer patients with mediastinal lymph node metastases, and the effect of survivin overexpression in the development of esophageal cancer. Dr. Battafarano sees patients at The Johns Hopkins Hospital and the Johns Hopkins Health Care & Surgery Centers at Green Spring Station and at White Marsh. Dr. Battafarano is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Gastrectomy, and Endoscopy. Dr. Battafarano is board certified in American Board Of Thoracic Surgery.

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy. Dr. Hales is board certified in American Board Of Radiology.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as an Experienced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Esophageal Cancer.